| Name | Title | Contact Details |
|---|
TRUE crafts naturally comfortable gear that transcends the links. Using only the finest materials, our shoes protect you from the elements and help you #enjoythewalk. As a collective we aim to inspire each other to achieve camaraderie, wellness and purpose in the pursuit of par.
Over 30 years ago, artist and designer Christopher Farr set out to unite heritage textile craftsmanship with contemporary design vision. Since then, he and his business partner Matthew Bourne have maintained a dedication to quality and an uncompromising pursuit of beauty that has helped revolutionise rug design and restore rug-making to the status of fine art. Each one made to order, Christopher Farr rugs are now a frequent sight at global art and design exhibitions, and in the homes of connoisseurs and collectors worldwide. Christopher Farr continues to protect and preserve the worlds weaving traditions, while pushing at the creative possibilities of design. Alongside Christophers own work, the company collaborates with a considered roster of international artists, architects, fashion designers and other visionaries to produce a selection of designs that remains unrivalled in its creative scope. Distribution is through showrooms located in London and Los Angeles as well as representation throughout the world. Collections include bespoke collaborations with designers such as Andrée Putman and John Pawson and artists including Gary Hume and Makoto Kagoshima. CF Editions collaborates with some of the worlds leading artists and designers, both past and present, including Josef and Anni Albers, Gunta Stölzl, Terry Frost and Sandra Blow. All designs are produced with the relevant institution, art gallery, estate or artist closely involved in the whole process and every rug is delivered with a signed certificate of authenticity. Unlike the made to order rugs, Editions are in stock and ready for delivery.
Tottenham Hotspur is a world-famous football club based in London. On the pitch, the Club competes in the upper echelons of the English Premier League and is a regular participant in marque UEFA club competitions. Off the pitch, the Club has a strong and successful business model centered around building a platform for long-term success, which includes a world-class training centre and now a brand new 62,214 seater world-class stadium. The Club operates out of multiple sites, including its Headquarters at Lilywhite House adjacent to the Tottenham Hotspur Stadium, the Training Centre, our state-of-the-art training facilities in Enfield or the Warehouse, the home of our Retail and Merchandise division in Brimsdown Were so proud of our rich history. From humble beginnings in North London, we became the first and, to date, only non-league side to win the FA Cup in 1901 – the first of eight triumphs in the age-old, world-renowned competition thus far.
MAXAM Tire North America is a global leader and manufacturer of specialty tires engineered and custom built specifically for OTR, construction, industrial and agricultural industries. MAXAM Tire has over 50+ years experience in designing, distributing and engineering high-quality specialty tires for markets all around the world. When it comes to serving customers, we deliver unmatched business solutions, service and support. Learn more at www.maxamtire.com
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.